Microsomal prostaglandin e synthase-1 and 5-lipoxygenase: Potential drug targets in cancer

Journal of Internal Medicine

Volumn 268, Issue 1, 2010, Pages 5-14

  Radmark O ^a   Samuelsson, B ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Arachidonic acid; Prostaglandins

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; PROSTAGLANDIN E SYNTHASE 1; PROSTAGLANDIN E2;

CANCER CELL; DRUG TARGETING; ENZYME INHIBITION; GENE DELETION; MICROSOME; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REVIEW; STROMA;

ANIMALS; ANTINEOPLASTIC AGENTS; ARACHIDONATE 5-LIPOXYGENASE; ENZYME INHIBITORS; GENE DELETION; HUMANS; INTRAMOLECULAR OXIDOREDUCTASES; MICE; MICROSOMES; NEOPLASMS;

EID: 77953526527     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2010.02246.x     Document Type: Review

References (87)

1. Samuelsson B, Goldyne M, Granstrom E, Hamberg M, Hammarstrom S, Malmsten C. Prostaglandins and thromboxanes. Annu Rev Biochem 1978 47 : 997 1029.
2. Samuelsson B, Morgenstern R, Jakobsson PJ. Membrane prostaglandin E synthase-1: a novel therapeutic target. Pharmacol Rev 2007 59 : 207 224.
3. Simmons DL, Botting RM, Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev 2004 56 : 387 437.
4. Capone ML, Tacconelli S, Di Francesco L, Sacchetti A, Sciulli MG, Patrignani P. Pharmacodynamic of cyclooxygenase inhibitors in humans. Prostaglandins Other Lipid Mediat 2007 82 : 85 94.
5. Burke JE, Dennis EA. Phospholipase A2 structure/function, mechanism, and signaling. J Lipid Res 2009 50 (Suppl. S237 42.
6. Ghosh M, Tucker DE, Burchett SA, Leslie CC. Properties of the Group IV phospholipase A2 family. Prog Lipid Res 2006 45 : 487 510.
7. Kobayashi T, Narumiya S. Function of prostanoid receptors: studies on knockout mice. Prostaglandins Other Lipid Mediat 2002 69 : 557 573.
8. Jakobsson PJ, Thoren S, Morgenstern R, Samuelsson B. Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc Natl Acad Sci U S A 1999 96 : 7220 7225.
9. Murakami M, Naraba H, Tanioka T et al. Regulation of prostaglandin E-2 biosynthesis by inducible membrane-associated prostaglandin E-2 synthase that acts in concert with cyclooxygenase-2. J Biol Chem 2000 275 : 32783 32792.
10. Thoren S, Jakobsson PJ. Coordinate up- and down-regulation of glutathione-dependent prostaglandin E synthase and cyclooxygenase-2 in A549 cells - inhibition by NS-398 and leukotriene C-4. Eur J Biochem 2000 267 : 6428 6434.
11. Jakobsson PJ, Morgenstern R, Mancini J, Ford-Hutchinson A, Persson B. Membrane-associated proteins in eicosanoid and glutathione metabolism (MAPEG) - a widespread protein superfamily. Am J Respir Crit Care Med 2000 161 : S20 4.
12. Holm PJ, Bhakat P, Jegerschold C et al. Structural basis for detoxification and oxidative stress protection in membranes. J Mol Biol 2006 360 : 934 945.
13. Jegerschold C, Pawelzik SC, Purhonen P et al. Structural basis for induced formation of the inflammatory mediator prostaglandin E2. Proc Natl Acad Sci U S A 2008 105 : 11110 11115.
14. Martinez Molina D, Wetterholm A, Kohl A et al. Structural basis for synthesis of inflammatory mediators by human leukotriene C4 synthase. Nature 2007 448 : 613 616.
15. Thoren S, Weinander R, Saha S et al. Human microsomal prostaglandin E synthase-1: purification, functional characterization, and projection structure determination. J Biol Chem 2003 278 : 22199 22209.
16. Ouellet M, Falgueyret JP, Ear PH et al. Purification and characterization of recombinant microsomal prostaglandin E synthase-1. Protein Expr Purif 2002 26 : 489 495.
17. Koeberle A, Rossi A, Zettl H et al. The molecular pharmacology and in vivo activity of 2-(4-chloro-6-(2,3-dimethylphenylamino)pyrimidin-2-ylthio) octanoic acid (YS121), a dual inhibitor of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase. J Pharmacol Exp Ther 2010 332 : 840 848.
18. Greenhough A, Smartt HJ, Moore AE et al. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 2009 30 : 377 386.
19. Wang D, Dubois RN. Eicosanoids and cancer. Nat Rev Cancer 2010 10 : 181 193.
20. Werz O, Steinhilber D. Therapeutic options for 5-lipoxygenase inhibitors. Pharmacol Ther 2006 112 : 701 718.
21. Marnett LJ. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 1992 52 : 5575 5589.
22. Castellone MD, Teramoto H, Gutkind JS. Cyclooxygenase-2 and colorectal cancer chemoprevention: the beta-catenin connection. Cancer Res 2006 66 : 11085 11088.
23. Cha YI, DuBois RN. NSAIDs and cancer prevention: targets downstream of COX-2. Annu Rev Med 2007 58 : 239 252.
24. McCarty MF. Targeting multiple signaling pathways as a strategy for managing prostate cancer: multifocal signal modulation therapy. Integr Cancer Ther 2004 3 : 349 380.
25. Nakanishi M, Gokhale V, Meuillet EJ, Rosenberg DW. mPGES-1 as a target for cancer suppression A comprehensive invited review 'Phospholipase A(2) and lipid mediators'. Biochimie 2010. [Epub ahead of print].
26. Patel MI, Kurek C, Dong Q. The arachidonic acid pathway and its role in prostate cancer development and progression. J Urol 2008 179 : 1668 1675.
27. Serafini P, Borrello I, Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 2006 16 : 53 65.
28. Wang MT, Honn KV, Nie D. Cyclooxygenases, prostanoids, and tumor progression. Cancer Metastasis Rev 2007 26 : 525 534.
29. Johnsen JI, Lindskog M, Ponthan F et al. NSAIDs in neuroblastoma therapy. Cancer Lett 2005 228 : 195 201.
30. DuBois RN. Evaluation of the whole prostaglandin biosynthetic pathway in lung cancer. Clin Cancer Res 2003 9 : 1577 1578.
31. Zha S, Gage WR, Sauvageot J et al. Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Res 2001 61 : 8617 8623.
32. St Sauver JL, Jacobson DJ, McGree ME, Lieber MM, Jacobsen SJ. Protective association between nonsteroidal antiinflammatory drug use and measures of benign prostatic hyperplasia. Am J Epidemiol 2006 164 : 760 768.
33. Patel MI, Singh J, Niknami M et al. Cytosolic phospholipase A2-{alpha}: a potential therapeutic target for prostate cancer. Clin Cancer Res 2008 14 : 8070 8079.
34. Hanaka H, Pawelzik SC, Johnsen JI et al. Microsomal prostaglandin E synthase 1 determines tumor growth in vivo of prostate and lung cancer cells. Proc Natl Acad Sci U S A 2009 106 : 18757 18762.
35. Cheng Y, Wang M, Yu Y, Lawson J, Funk CD, Fitzgerald GA. Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J Clin Invest 2006 116 : 1391 1399.
36. Nakanishi M, Montrose DC, Clark P et al. Genetic deletion of mPGES-1 suppresses intestinal tumorigenesis. Cancer Res 2008 68 : 3251 3259.
37. Elander N, Ungerback J, Olsson H, Uematsu S, Akira S, Soderkvist P. Genetic deletion of mPGES-1 accelerates intestinal tumorigenesis in APC(Min/+) mice. Biochem Biophys Res Commun 2008 372 : 249 253.
38. Kamei D, Murakami M, Sasaki Y et al. Microsomal prostaglandin E synthase-1 in both cancer cells and hosts contributes to tumour growth, invasion and metastasis. Biochem J 2010 425 : 361 371.
39. Shao J, Jung C, Liu C, Sheng H. Prostaglandin E2 Stimulates the beta-catenin/T cell factor-dependent transcription in colon cancer. J Biol Chem 2005 280 : 26565 26572.
40. Attiga FA, Fernandez PM, Weeraratna AT, Manyak MJ, Patierno SR. Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Res 2000 60 : 4629 4637.
41. Jain S, Chakraborty G, Raja R, Kale S, Kundu GC. Prostaglandin E2 regulates tumor angiogenesis in prostate cancer. Cancer Res 2008 68 : 7750 7759.
42. Eriksson SE, Prast-Nielsen S, Flaberg E, Szekely L, Arner ES. High levels of thioredoxin reductase 1 modulate drug-specific cytotoxic efficacy. Free Radic Biol Med 2009 47 : 1661 1671.
43. Oshima H, Oshima M, Inaba K, Taketo MM. Hyperplastic gastric tumors induced by activated macrophages in COX-2/mPGES-1 transgenic mice. EMBO J 2004 23 : 1669 1678.
44. Maggio-Price L, Treuting P, Zeng W, Tsang M, Bielefeldt-Ohmann H, Iritani BM. Helicobacter infection is required for inflammation and colon cancer in SMAD3-deficient mice. Cancer Res 2006 66 : 828 838.
45. Lalier L, Cartron PF, Pedelaborde F et al. Increase in PGE2 biosynthesis induces a Bax dependent apoptosis correlated to patients' survival in glioblastoma multiforme. Oncogene 2007 26 : 4999 5009.
46. Oshima M, Dinchuk JE, Kargman SL et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996 87 : 803 809.
47. Williams CS, Tsujii M, Reese J, Dey SK, DuBois RN. Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 2000 105 : 1589 1594.
48. Ishikawa TO, Herschman HR. Tumor formation in a mouse model of colitis associated colon cancer does not require COX-1 or COX-2 expression. Carcinogenesis 2010 31 : 729 736.
49. Gupta GP, Nguyen DX, Chiang AC et al. Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature 2007 446 : 765 770.
50. Folco G, Murphy RC. Eicosanoid transcellular biosynthesis: from cell-cell interactions to in vivo tissue responses. Pharmacol Rev 2006 58 : 375 388.
51. Salvado MD, Alfranca A, Escolano A, Haeggstrom JZ, Redondo JM. COX-2 limits prostanoid production in activated HUVECs and is a source of PGH2 for transcellular metabolism to PGE2 by tumor cells. Arterioscler Thromb Vasc Biol 2009 29 : 1131 1137.
52. Radilova H, Libra A, Holasova S et al. COX-1 is coupled with mPGES-1 and ABCC4 in human cervix cancer cells. Mol Cell Biochem 2009 330 : 131 140.
53. Subbarayan V, Sabichi AL, Llansa N, Lippman SM, Menter DG. Differential expression of cyclooxygenase-2 and its regulation by tumor necrosis factor-alpha in normal and malignant prostate cells. Cancer Res 2001 61 : 2720 2726.
54. Kamei D, Murakami M, Nakatani Y, Ishikawa Y, Ishii T, Kudo I. Potential role of microsomal prostaglandin E synthase-1 in tumorigenesis. J Biol Chem 2003 278 : 19396 19405.
55. Peters-Golden M, Henderson WR Jr. Leukotrienes. N Engl J Med 2007 357 : 1841 1854.
56. Rådmark O, Werz O, Steinhilber D, Samuelsson B. 5-Lipoxygenase: regulation of expression and enzyme activity. Trends Biochem Sci 2007 32 : 332 341.
57. Esser J, Rakonjac M, Hofmann B et al. Coactosin-like protein functions as a stabilizing chaperone for 5-lipoxygenase: role of tryptophan 102. Biochem J 2010 425 : 265 274.
58. Rakonjac M, Fischer L, Provost P et al. Coactosin-like protein supports 5-lipoxygenase enzyme activity and up-regulates leukotriene A4 production. Proc Natl Acad Sci U S A 2006 103 : 13150 13155.
59. Nakatsura T, Senju S, Ito M, Nishimura Y, Itoh K. Cellular and humoral immune responses to a human pancreatic cancer antigen, coactosin-like protein, originally defined by the SEREX method. Eur J Immunol 2002 32 : 826 836.
60. Cecconi D, Astner H, Donadelli M et al. Proteomic analysis of pancreatic ductal carcinoma cells treated with 5-aza-2′-deoxycytidine. Electrophoresis 2003 24 : 4291 4303. (Pubitemid 38094474)
61. Peters-Golden M, Brock TG. 5-Lipoxygenase and FLAP. Prostaglandins Leukot Essent Fatty Acids 2003 69 : 99 109.
62. Mandal AK, Jones PB, Bair AM et al. The nuclear membrane organization of leukotriene synthesis. Proc Natl Acad Sci U S A 2008 105 : 20434 20439.
63. Pergola C, Dodt G, Rossi A et al. ERK-mediated regulation of leukotriene biosynthesis by androgens: a molecular basis for gender differences in inflammation and asthma. Proc Natl Acad Sci U S A 2008 105 : 19881 19886.
64. Furstenberger G, Krieg P, Muller-Decker K, Habenicht AJ. What are cyclooxygenases and lipoxygenases doing in the driver's seat of carcinogenesis? Int J Cancer 2006 119 : 2247 2254.
65. Ghosh J. Rapid induction of apoptosis in prostate cancer cells by selenium: reversal by metabolites of arachidonate 5-lipoxygenase. Biochem Biophys Res Commun 2004 315 : 624 635.
66. Covey TM, Edes K, Fitzpatrick FA. Akt activation by arachidonic acid metabolism occurs via oxidation and inactivation of PTEN tumor suppressor. Oncogene 2007 26 : 5784 5792.
67. Catalano A, Caprari P, Soddu S, Procopio A, Romano M. 5-Lipoxygenase antagonizes genotoxic stress-induced apoptosis by altering p53 nuclear trafficking. FASEB J 2004 18 : 1740 1742. [Epub 2004 September 16].
68. Choi EM, Heo JI, Oh JY et al. COX-2 regulates p53 activity and inhibits DNA damage-induced apoptosis. Biochem Biophys Res Commun 2005 328 : 1107 1112.
69. Han JA, Kim JI, Ongusaha PP et al. P53-mediated induction of Cox-2 counteracts p53- or genotoxic stress-induced apoptosis. EMBO J 2002 21 : 5635 5644.
70. Hennig R, Ding XZ, Tong WG et al. 5-Lipoxygenase and leukotriene B(4) receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue. Am J Pathol 2002 161 : 421 428.
71. Massoumi R, Sjolander A. The role of leukotriene receptor signaling in inflammation and cancer. ScientificWorldJournal 2007 7 : 1413 1421.
72. Sveinbjornsson B, Rasmuson A, Baryawno N et al. Expression of enzymes and receptors of the leukotriene pathway in human neuroblastoma promotes tumor survival and provides a target for therapy. FASEB J 2008 22 : 3525 3536.
73. Zarini S, Gijon MA, Ransome AE, Murphy RC, Sala A. Transcellular biosynthesis of cysteinyl leukotrienes in vivo during mouse peritoneal inflammation. Proc Natl Acad Sci U S A 2009 106 : 8296 8301.
74. Friesen RW, Mancini JA. Microsomal prostaglandin E2 synthase-1 (mPGES-1): a novel anti-inflammatory therapeutic target. J Med Chem 2008 51 : 4059 4067.
75. Koeberle A, Werz O. Inhibitors of the microsomal prostaglandin E(2) synthase-1 as alternative to non steroidal anti-inflammatory drugs (NSAIDs) - a critical review. Curr Med Chem 2009 16 : 4274 4296.
76. Giroux A, Boulet L, Brideau C et al. Discovery of disubstituted phenanthrene imidazoles as potent, selective and orally active mPGES-1 inhibitors. Bioorg Med Chem Lett 2009 19 : 5837 5841.
77. Riendeau D, Aspiotis R, Ethier D et al. Inhibitors of the inducible microsomal prostaglandin E2 synthase (mPGES-1) derived from MK-886. Bioorg Med Chem Lett 2005 15 : 3352 3355.
78. Koeberle A, Northoff H, Werz O. Curcumin blocks prostaglandin E2 biosynthesis through direct inhibition of the microsomal prostaglandin E2 synthase-1. Mol Cancer Ther 2009 8 : 2348 2355.
79. Koeberle A, Bauer J, Verhoff M, Hoffmann M, Northoff H, Werz O. Green tea epigallocatechin-3-gallate inhibits microsomal prostaglandin E(2) synthase-1. Biochem Biophys Res Commun 2009 388 : 350 354.
80. Romano M, Claria J. Cyclooxygenase-2 and 5-lipoxygenase converging functions on cell proliferation and tumor angiogenesis: implications for cancer therapy. FASEB J 2003 17 : 1986 1995.
81. Steinbrink SD, Pergola C, Buhring U et al. Sulindac sulfide suppresses 5-lipoxygenase at clinically relevant concentrations. Cell Mol Life Sci 2009 67 : 797 806.
82. Melstrom LG, Bentrem DJ, Salabat MR et al. Overexpression of 5-lipoxygenase in colon polyps and cancer and the effect of 5-LOX inhibitors in vitro and in a murine model. Clin Cancer Res 2008 14 : 6525 6530.
83. Fischer L, Hornig M, Pergola C et al. The molecular mechanism of the inhibition by licofelone of the biosynthesis of 5-lipoxygenase products. Br J Pharmacol 2007 152 : 471 480.
84. Koeberle A, Siemoneit U, Buhring U et al. Licofelone suppresses prostaglandin E2 formation by interference with the inducible microsomal prostaglandin E2 synthase-1. J Pharmacol Exp Ther 2008 326 : 975 982.
85. Koeberle A, Northoff H, Werz O. Identification of 5-lipoxygenase and microsomal prostaglandin E2 synthase-1 as functional targets of the anti-inflammatory and anti-carcinogenic garcinol. Biochem Pharmacol 2009 77 : 1513 1521.
86. Koeberle A, Haberl EM, Rossi A et al. Discovery of benzo[g]indol-3- carboxylates as potent inhibitors of microsomal prostaglandin E(2) synthase-1. Bioorg Med Chem 2009 17 : 7924 7932.
87. Werz O, Greiner C, Koeberle A et al. Novel and potent inhibitors of 5-lipoxygenase product synthesis based on the structure of pirinixic acid. J Med Chem 2008 51 : 5449 5453.